RFA 1 Level III-3 study Median survival rate, pooled ⨁⨀⨀⨀ VERY LOW 3 Assessed with: 7 Level IV studies 1-year 86.3% (range 83–100%) estimate (95%CI not 2-year 74% (range 69.8–86%) reported) 3-year 62.8% (range 40–74%) F/U range 19 to 46 months 5-year 28% (range 14–61%) Radiotherapy 1 Level II study Videtic et al (2015) ⨁⨁⨀⨀ Assessed with: varied 1 Level III-1 1-year survival LOW instruments study5 34/1 GY SBRT = 48.6% (95% CI 68.9–92.8%) F/U range 21 to 30.2 48/4 GY SBRT = 91.1 (95% CI 78.0–96.6%) months 2-year survival 34/1 GY SBRT = 61.3% (95% CI 44.2–74.6%) 48/4 GY SBRT = 77.7% (95% CI 62.5–87.3%) Koshy et al (2015) 3-year survival No therapy = 28% , Conventional radiotherapy = 36%, SBRT = 48% A propensity-matched cohort reported 3 year overall survival with SBRT of 48% and with conventional radiotherapy of 40% (p = 0.001). Median survival time MTA 2 Level IV studies Han et al (2015) ⨁⨀⨀⨀ VERY LOW 5 Assessed with: 35.0 months (95%CI 22.3–47.7) estimate (95%CI) Yang et al (2014) F/U range 23 to 30 months 33.8 months (95%CI 31.9–35.7) 2 RFA 6 Level IV studies Median overall survival 42.8 months (range: ⨁⨀⨀⨀ 33.4–67) VERY LOW 3 Assessed with: estimate (95%CI) F/U range 19 to 37 months Radiotherapy 0 studies NA NA Not reported Time to local progression
RFA Assessed with: estimate (95%CI not reported) F/U range 19 to 46 months 1 Level III-3 study 7 Level IV studies Median survival rate, pooled 1-year 86.3% (range 83–100%) 2-year 74% (range 69.8–86%) 3-year 62.8% (range 40–74%) 5-year 28% (range 14–61%) ⨁⨀⨀⨀ VERY LOW 3 Radiotherapy Assessed with: varied instruments F/U range 21 to 30.2 months 1 Level II study 1 Level III-1 study5 Videtic et al (2015) 1-year survival 34/1 GY SBRT = 48.6% (95% CI 68.9–92.8%) 48/4 GY SBRT = 91.1 (95% CI 78.0–96.6%) 2-year survival 34/1 GY SBRT = 61.3% (95% CI 44.2–74.6%) 48/4 GY SBRT = 77.7% (95% CI 62.5–87.3%) Koshy et al (2015) 3-year survival No therapy = 28% , Conventional radiotherapy = 36%, SBRT = 48% A propensity-matched cohort reported 3 year overall survival with SBRT of 48% and with conventional radiotherapy of 40% (p = 0.001). ⨁⨁⨀⨀ LOW Median survival time MTA Assessed with: estimate (95%CI) F/U range 23 to 30 months 2 Level IV studies Han et al (2015) 35.0 months (95%CI 22.3–47.7) Yang et al (2014) 33.8 months (95%CI 31.9–35.7) 2 ⨁⨀⨀⨀ VERY LOW 5 RFA Assessed with: estimate (95%CI) F/U range 19 to 37 months 6 Level IV studies Median overall survival 42.8 months (range: 33.4–67) ⨁⨀⨀⨀ VERY LOW 3 Radiotherapy Not reported 0 studies NA NA Time to local progression
1403%20-%20Final%20Contracted%20Assessment%20Report%20(ACCESSIBLE).docx